Skip to main content

Passage BIO, Inc.

PASG
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001787297

No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Passage BIO, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of PASG: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders8776−11
Shares42.2M39.4M−2.77M (−6.6%)
Value$99.6M$49.3M−$50.3M (−50.5%)

New holders (9)

Institutions that held Passage BIO, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to PASG in Q3 2022
InstitutionSharesValue% of portfolio
Bridgeway Capital Management, LLC163,100$204.0K0.01%
Annandale Capital, LLC40,000$50.0K0.02%
Jane Street Group, LLC17,712$22.0K0.00%
UBS Group AG11,849$15.0K0.00%
Squarepoint Ops LLC11,013$14.0K0.00%
Fiduciary Trust Co10,000$13.0K0.00%
Point72 Hong Kong Ltd3,400$4.00K0.00%
Global Trust Asset Management, LLC537$1.00K0.00%
China Universal Asset Management Co., Ltd.510$1.00K0.00%

Sold out (20)

Institutions that held Passage BIO, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.